Approximately 40% of colorectal cancer patients will develop colorectal liver metastases
(CRLM). The most effective approach to increase long-term survival is CRLM complete
resection. Unfortunately, only 10 - 15% of CRLM are initially considered resectable. The
objective response rates (ORR) after current first-line systemic chemotherapy (sys-CT)
regimens range from 40 to 80% and complete resection rates (CRR) range from 25 to 50% in
patients with initially unresectable CRLM. When CRLM patients are not amenable to complete
resection after induction of sys-CT, ORRs obtained with second-line sys-CT are much lower
(between 10 and 30%) and consequently CRRs are also low (< 10%). Hepatic arterial infusion
(HAI) oxaliplatin may represent a salvage therapy in patients with CRLM unresectable after
one or more sys-CT regimens with ORRs and CRRs up to 60 and 30%, respectively. This study is
designed to evaluate the efficacy of an intensification strategy based on HAI oxaliplatin
combined with sys-CT as the first-line treatment in patients with unresectable CRLM.
Metastatic Colorectal Cancer
intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks,
IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.